DUOSTIM and AI: is There a Difference Between Oocyte Performance in the Follicular and Luteal Phases?

NCT ID: NCT06799598

Last Updated: 2025-01-29

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

92 participants

Study Classification

OBSERVATIONAL

Study Start Date

2024-05-01

Study Completion Date

2025-01-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In vitro fertilization (IVF) has revolutionized assisted reproductive techniques, bringing hope to thousands of people seeking to fulfill their dream of parenthood. However, patients with low ovarian reserve face additional challenges, such as limited response to ovarian stimulation and difficulty in obtaining good-quality eggs. Innovative protocols such as Duostim (dual stimulation) have shown promise in these cases, allowing the maximum number of eggs to be retrieved in a short period of time. In addition, technological advances in the analysis of the quality of mature eggs, such as the use of the Magenta tool, are transforming the way specialists evaluate and select the best gametes to increase the chances of success. This article explores how these approaches complement each other, offering new possibilities for patients with low ovarian reserve and raising the standards of reproductive medicine.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The analysis of the two stimulation phases in a Duostim protocol for IVF using the Magenta tool may have significant clinical relevance, especially in the context of patients with low ovarian reserve or who require optimization in the number of embryos available in IVF cycles in a short period of time. The Magenta tool, being based on AI and machine learning, can identify patterns related to the quality of oocytes and embryos obtained in both phases. This can help determine if there are significant differences in embryo competence between oocytes collected in the follicular phase and the luteal phase. Magenta-powered analysis can provide robust data to validate the Duostim protocol, identify subgroups that benefit most from it, and promote greater clinical efficiency in IVF treatments, especially in challenging cases. This approach can revolutionize the way personalized protocols are designed and monitored to maximize reproductive success. The aim of this study is to compare the two phases of ovarian stimulation - follicular and luteal - in patients undergoing the Duostim protocol, using the Magenta tool for detailed analysis of mature eggs obtained in each phase. The research seeks to identify differences in oocyte quality between the two stages, as well as to evaluate the efficiency of the protocol in maximizing results in patients with low ovarian reserve.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Infertility

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

OTHER

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

DuoStim1

Follicular phase Stimulation

No interventions assigned to this group

DuoStim2

Luteal Phase stimulation

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients undergoing IVF with DUOSTIM protocol and Magenta analysis of mature eggs.

Exclusion Criteria

* Canceled Duostim Magenta IVF cycles
Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Rio de Janeiro State University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Yuri Ian Lima Alves de Oliveira

M.D.

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Vida - Medicina Reprodutiva

Rio de Janeiro, Rio de Janeiro, Brazil

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Brazil

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

VD001/2025

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Use of IMSI in Poor Responders to IVF
NCT02358733 TERMINATED NA
Prediction of Ovarian Response
NCT00557687 COMPLETED
Selection of Embryos by Time-lapse
NCT01138631 COMPLETED NA